Skip to main content
< Back to news
Researcher Nuria Montserrat with members of her team (Photo: IBEC).

Researchers at IBEC help identifying a drug in clinical phase that blocks the effects of SARS-Co-V2

IBEC researchers led by ICREA Research Professor Núria Montserrat at the Barcelona Science Park, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.9.


The treatment, which can be tested on two hundred Covid-19 patients as of today, has proven effective in mini-kidneys generated from human stem cells. Using hese organoids generated by bioengineering techniques, it has been deciphered how SARS-Co-V2 interacts and infects human kidney cells.

To carry out the study, published today in the prestigious journal Cell, the experts have used mini-kidneys created from human stem cells generated at  IBEC’s Pluripotency for organ regeneration group, leaded by Nuria Montserrat.

These organoids, which have been obtained applying bioengineering techniques, reproduce the complexity of the real organ and allowed the researchers to decipher how SARS-Co-V2 interacts and infects human kidney cells. Moreover, they have validated a therapy able to reduce substantially viral load of COVID-19. 

“The use of human organoids allows us to test in a very agile way the treatments that are already being used for other diseases or that are close to being validated. When time is short, these 3D structures dramatically reduce the time we would spend trying a new drug on humans” states Núria Montserrat. 

► Reference article: Monteil et al. “Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2“. Cell 2020, DOI: 10.1016/j.cell.2020.04.004

► For further information: IBEC website [+]